规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
在 A431 细胞中,苯磺酸氨氯地平(20–40 μM;48 小时)在 20 和 30 μM 时将 BrdU 掺入率分别降低至 68.6% 和 26.3%[3]。在 A431 细胞中,苯磺酸氨氯地平(30 μM;预处理 1 小时)可大大减弱尿苷 5'-三磷酸 (UTP) 诱导的 [Ca2+]i 升高[3]。在装载 Fluo-3 的细胞中,苯磺酸氨氯地平 (30 μM) 抑制毒胡萝卜素触发的钙池操纵的 Ca2+ 内流[3]。
|
---|---|
体内研究 (In Vivo) |
在 VSMC ATP2B1 KO 小鼠中,苯磺酸氨氯地平(5 mg/kg/天;皮下注射 2 周)可显着降低收缩压 (SBP)[4]。苯磺酸氨氯地平(10mg/kg;腹腔注射;每日一次,持续20天)治疗可显着抑制肿瘤的形成,并延长A431荷瘤小鼠的寿命[3]。
|
动物实验 |
Animal/Disease Models: ATP2B1loxP/loxP mice[4]
Doses: 5 mg/kg/day Route of Administration: subcutaneously (sc) implanted osmotic pump for 2 weeks Experimental Results: Dramatically diminished the blood pressure. |
参考文献 |
[1]. Yoshida J, et, al. Antitumor effects of amlodipine, a Ca2+ channel blocker, on human epidermoid carcinoma A431 cells in vitro and in vivo. Eur J Pharmacol. 2004 May 25;492(2-3):103-12.
[2]. Okuyama Y, et, al. The effects of anti-hypertensive drugs and the mechanism of hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice. Hypertens Res. 2018 Feb;41(2):80-87. [3]. Kishen G. Bulsara, et al. Amlodipine. [4]. Haria M, et al. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published correction appears in Drugs 1995 Nov;50(5):896]. Drugs. 1995;50(3):560-586. |
分子式 |
C20H25CLN2O5.C6H6O3S
|
|
---|---|---|
分子量 |
567.05
|
|
CAS号 |
111470-99-6
|
|
相关CAS号 |
Amlodipine;88150-42-9;Amlodipine maleate;88150-47-4;Amlodipine-d4 besylate;Amlodipine mesylate;246852-12-0
|
|
SMILES |
ClC1=C([H])C([H])=C([H])C([H])=C1C1([H])C(C(=O)OC([H])([H])[H])=C(C([H])([H])[H])N([H])C(C([H])([H])OC([H])([H])C([H])([H])N([H])[H])=C1C(=O)OC([H])([H])C([H])([H])[H].S(C1C([H])=C([H])C([H])=C([H])C=1[H])(=O)(=O)O[H]
|
|
InChi Key |
ZPBWCRDSRKPIDG-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
|
|
化学名 |
3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (+-)-, monobenzenesulfonate
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7635 mL | 8.8176 mL | 17.6351 mL | |
5 mM | 0.3527 mL | 1.7635 mL | 3.5270 mL | |
10 mM | 0.1764 mL | 0.8818 mL | 1.7635 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02353806 | Completed Has Results | Drug: Amlodipine besylate | Chronic Hypertension in Pregnancy | University of Texas Southwestern Medical Center |
January 2015 | Phase 4 |
NCT05667818 | Not yet recruiting | Drug: Amlodipine besylate tablets (trade name: Norfloxacin ®) | Hypertension | Overseas Pharmaceuticals, Ltd. | January 28, 2023 | Phase 1 |
NCT01155908 | Completed | Drug: Amlodipine Besylate / Benazepril Hydrochloride |
Healthy | Dr. Reddy's Laboratories Limited | April 2005 | Phase 1 |
NCT02940548 | Terminated | Drug: Nifedipine GITS Drug: Amlodipine besylate |
Hypertension | Jing Liu | December 2016 | Phase 4 |